Clinical Trial Update: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer [Phase 1]

View source ↗

Summary

This Clinical Trials Update describes a Phase 1 study of an Fc-engineered anti-CTLA-4 monoclonal antibody by Agenus in patients with advanced cancers, including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Colorectal Cancer
• Endometrial Cancer
• Fibrolamellar Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• Fc-engineered anti-CTLA-4 monoclonal antibody

Snippet

Sponsor: Agenus Inc. | Conditions: Advanced Cancer, Angiosarcoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING